ERBB2 and breast cancer: Tumorigenicity attenuation in breast cancer by BKCa channel inhibition was a result of depolarizing shifts in cell transmembrane potential and subsequent downregulation of β-catenin and (phospho) Akt and HER-2/neu protein levels [50].